Serina Therapeutics (NYSEAMERICAN:SER) Trading 5.2% Higher – Here’s What Happened

Serina Therapeutics, Inc. (NYSEAMERICAN:SER)’s share price traded up 5.2% during mid-day trading on Wednesday . The stock traded as high as $2.07 and last traded at $2.03. 81,064 shares were traded during mid-day trading, a decline of 99% from the average session volume of 10,031,279 shares. The stock had previously closed at $1.93.

Serina Therapeutics Price Performance

The company’s fifty day moving average is $1.93. The company has a market cap of $24.99 million, a price-to-earnings ratio of -1.06 and a beta of 1.21.

Serina Therapeutics (NYSEAMERICAN:SER) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.31) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In related news, insider Randall Moreadith sold 39,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $2.50, for a total transaction of $97,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 63,000 shares of company stock worth $172,365 in the last ninety days. Company insiders own 17.00% of the company’s stock.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.